Biocompatible and target specific hydrophobically modified glycol chitosan nanoparticles

Area of Science:

• Biomaterials Science
• Nanotechnology
• Cardiovascular Research

Background:

• Cardiovascular disease (CVD) is a leading cause of mortality.
• Atherosclerosis, a primary contributor to CVD, is often treated with nonspecific drugs.
• Enhanced drug delivery specificity is crucial for effective atherosclerosis treatment.

Purpose of the Study:

• To develop and evaluate hydrophobically modified glycol chitosan (HGC) nanoparticles for targeted drug delivery.
• To assess the biocompatibility of HGC nanoparticles with blood components and vascular endothelial cells.
• To determine the targeting specificity of HGC nanoparticles towards activated endothelial cells.

Main Methods:

• Hemolysis, platelet activation, thrombogenicity, and aggregation assays were used to evaluate nanoparticle biocompatibility with blood cells.
• Endothelial cell growth, metabolic activity, and activation were assessed to determine nanoparticle effects.
• HGC nanoparticles were conjugated with intercellular adhesion molecule 1 antibodies to test targeting specificity.

Main Results:

• HGC nanoparticles demonstrated no hemolysis or adverse effects on platelet function (activation, thrombogenicity, aggregation).
• Nanoparticles did not impede vascular endothelial cell growth or metabolic activity, nor induce cell activation.
• Conjugation with intercellular adhesion molecule 1 antibodies significantly enhanced nanoparticle targeting of activated endothelial cells.

Conclusions:

• HGC nanoparticles exhibit excellent biocompatibility with red blood cells, platelets, and endothelial cells.
• These nanoparticles show potential for identifying activated endothelial cells in atherosclerotic lesions.
• HGC nanoparticles could serve as a platform for targeted therapeutic drug delivery in atherosclerosis.